Wolfe Research Lowers Meta Price Target to $700
Wolfe Research analyst Shweta Khajuria lowered the price target on Meta Platforms Inc.
(NASDAQ: META) to $700 (from $800) while maintaining an Outperform rating.
“Meta’s EPS call left investors wanting for more, especially as Ad revenue decelerates in H2 and CapEx remains elevated.
Specifically, no commentary on: a) timeline for generating incremental Rev. from renting excess capacity; b) framework for ROIC from new Rev. sources; c) capital raises vs. new JVs in the NT; d) framework on magnitude of Rev. or TAM of new monetization opportunities.
Management’s message implied ongoing, elevated CapEx through 2028.
That said, they provided some additional color on new & existing revenue lines which included: a) Core business strength driven by LLM-native rec systems, improved ROAS, new content, and products shipped faster; b) Personal AI agents for consumers; c) Business AI agents & API plug-ins for SMBs and Enterprises; d) Selling compute + new Enterprise products.
It now becomes an execution story. We are raising our ’27 CapEx to $233B, implying 6-7GW of new capacity, and expect Meta to raise $50 – $100B over the next 3 – 18 months.
Q2 Revenue of $61B came in 1% above the Street, with 14% impressions growth and 12% pricing growth. OI of $22B (ex-one time costs) came in above the Street. Q3 revenue guide of $64B at high-end (vs.
Street at $63B) came largely in line with investor expectations. Management narrowed CapEx and OpEx guides.
Meta’s fundamentals remain healthy but spend against current revenue seems unjustifiable until we see more evidence.”
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.
This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.




